OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA, A DEMIRCI, D SINDHUNATA, J BACKHUS, H ALGÜL, J BUIJS, P LEVY, M KIRIUKOVA, E GONI, M HOLLENBACH, R MIKSCH, Lumír KUNOVSKÝ, M VUJASINOVIC, S NIKOLIC, L DICKERSON, M HIRTH, M NEURATH, M ZUMBLICK, J VILA, M JALAL, G BEYER, F FROST, S CARRARA, Zdeněk KALA, Petr JABANDŽIEV, G SISMAN, F AKYUZ, G CAPURSO, M FALCONI, A ARLT, F VLEGGAAR, L BARRESI, B GREENHALF, L CZAKÓ, P HEGYI, A HOPPER, M NAYAR, T GRESS, F VITALI, A SCHNEIDER, C HALLORAN, Jan TRNA, A OKHLOBYSTIN, L DAGNA, D CAHEN, D BORDIN, V REBOURS, J MAYERLE, A KAHRAMAN, S RASCH, E CULVER, A KLEGER, E MARTÍNEZ-MONEO, O RØKKE, T HUCL, S OLESEN, M BRUNO, E DELLA-TORRE, U BEUERS, J LÖHR a J ROSENDAHL. Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. In 54th meeting of the European Pancreatic Club. 2022. ISSN 1424-3903. Dostupné z: https://dx.doi.org/10.1016/j.pan.2022.06.036. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2233423, author = {Overbeek, Kasper A and Poulsen, J and Lanzillotta, M and VingeandHolmquist, O and Macinga, P and Demirci, A and Sindhunata, D and Backhus, J and Algül, H and Buijs, J and Levy, P and Kiriukova, M and Goni, E and Hollenbach, M and Miksch, R and Kunovský, Lumír and Vujasinovic, M and Nikolic, S and Dickerson, L and Hirth, M and Neurath, M and Zumblick, M and Vila, J and Jalal, M and Beyer, G and Frost, F and Carrara, S and Kala, Zdeněk and Jabandžiev, Petr and Sisman, G and Akyuz, F and Capurso, G and Falconi, M and Arlt, A and Vleggaar, F and Barresi, L and Greenhalf, B and Czakó, L and Hegyi, P and Hopper, A and Nayar, M and Gress, T and Vitali, F and Schneider, A and Halloran, C and Trna, Jan and Okhlobystin, A and Dagna, L and Cahen, D and Bordin, D and Rebours, V and Mayerle, J and Kahraman, A and Rasch, S and Culver, E and Kleger, A and MartínezandMoneo, E and Røkke, O and Hucl, T and Olesen, S and Bruno, M and DellaandTorre, E and Beuers, U and Löhr, J and Rosendahl, J}, booktitle = {54th meeting of the European Pancreatic Club}, doi = {http://dx.doi.org/10.1016/j.pan.2022.06.036}, language = {eng}, title = {Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment}, url = {https://www.sciencedirect.com/science/article/pii/S1424390322002319}, year = {2022} }
TY - CONF ID - 2233423 AU - Overbeek, Kasper A - Poulsen, J - Lanzillotta, M - Vinge-Holmquist, O - Macinga, P - Demirci, A - Sindhunata, D - Backhus, J - Algül, H - Buijs, J - Levy, P - Kiriukova, M - Goni, E - Hollenbach, M - Miksch, R - Kunovský, Lumír - Vujasinovic, M - Nikolic, S - Dickerson, L - Hirth, M - Neurath, M - Zumblick, M - Vila, J - Jalal, M - Beyer, G - Frost, F - Carrara, S - Kala, Zdeněk - Jabandžiev, Petr - Sisman, G - Akyuz, F - Capurso, G - Falconi, M - Arlt, A - Vleggaar, F - Barresi, L - Greenhalf, B - Czakó, L - Hegyi, P - Hopper, A - Nayar, M - Gress, T - Vitali, F - Schneider, A - Halloran, C - Trna, Jan - Okhlobystin, A - Dagna, L - Cahen, D - Bordin, D - Rebours, V - Mayerle, J - Kahraman, A - Rasch, S - Culver, E - Kleger, A - Martínez-Moneo, E - Røkke, O - Hucl, T - Olesen, S - Bruno, M - Della-Torre, E - Beuers, U - Löhr, J - Rosendahl, J PY - 2022 TI - Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment UR - https://www.sciencedirect.com/science/article/pii/S1424390322002319 N2 - Introduction: Autoimmune pancreatitis (AIP) is a rare disease. Large-scale studies from Europe are lacking, and there is little evidence on the optimum treatment regimen. Purpose: To characterize AIP patients in a large pan-European cohort, study the effectiveness of current treatment regimens, and compare these to non-European cohorts. Materials and methods: We retrospectively analyzed all adults diagnosed since 2005 with AIP type 1 or not-otherwise-specified, who had not undergone pancreatic surgery, in 40 European university hospitals. Results: We screened 1079 individuals with suspected AIP, and included 735 for analysis (69% male; median age 57 years; 85% Caucasian). Rates of complete remission were 61% for those untreated (58/95) and 72% for steroid treatment (454/631). Rates of any remission (complete or partial) were 80% (76/95) for the untreated and 96% (603/631) for steroid-treated patients. Higher steroid doses were not more effective than lower doses (OR 0.428; 95%CI 0.054-3.387) and neither was a starting dose duration longer than two weeks (OR 0.908; 95%CI 0.818-1.009). Elevated IgG4 levels independently decreased the chance of complete remission (OR 0.639; 95%CI 0.427-0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid tapering duration, remission induction treatment duration, and total cumulative dose. Conclusions: European AIP patients display a slightly different demography, but the same presentation and course of disease as non-European populations. Their response to steroid treatment seems slightly lower. Patients with an elevated IgG4 level may need closer monitoring during remission induction. For remission induction, a starting dose of 0.4 mg/kg/day with a minimum of 20 mg for 2 weeks is an effective treatment regimen and there is no evidence to support more aggressive regimens. ER -
OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA, A DEMIRCI, D SINDHUNATA, J BACKHUS, H ALGÜL, J BUIJS, P LEVY, M KIRIUKOVA, E GONI, M HOLLENBACH, R MIKSCH, Lumír KUNOVSKÝ, M VUJASINOVIC, S NIKOLIC, L DICKERSON, M HIRTH, M NEURATH, M ZUMBLICK, J VILA, M JALAL, G BEYER, F FROST, S CARRARA, Zdeněk KALA, Petr JABANDŽIEV, G SISMAN, F AKYUZ, G CAPURSO, M FALCONI, A ARLT, F VLEGGAAR, L BARRESI, B GREENHALF, L CZAKÓ, P HEGYI, A HOPPER, M NAYAR, T GRESS, F VITALI, A SCHNEIDER, C HALLORAN, Jan TRNA, A OKHLOBYSTIN, L DAGNA, D CAHEN, D BORDIN, V REBOURS, J MAYERLE, A KAHRAMAN, S RASCH, E CULVER, A KLEGER, E MARTÍNEZ-MONEO, O RØKKE, T HUCL, S OLESEN, M BRUNO, E DELLA-TORRE, U BEUERS, J LÖHR a J ROSENDAHL. Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. In \textit{54th meeting of the European Pancreatic Club}. 2022. ISSN~1424-3903. Dostupné z: https://dx.doi.org/10.1016/j.pan.2022.06.036.
|